STOCK TITAN

Tax-driven share sale and RSU vesting for Nurix (NRIX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring had restricted stock units vest and related share movements on April 30, 2026. She sold 3,214 shares of common stock at a weighted average of $16.6453 per share solely to cover tax withholding on the RSU vesting, under the company’s mandatory “sell to cover” policy, so the sale was not a discretionary trade. In connection with the vesting, she acquired a total of 8,608 shares of common stock through RSU conversions.

Positive

  • None.

Negative

  • None.
Insider Ring Christine
Role Chief Legal Officer
Sold 3,214 shs ($53K)
Type Security Shares Price Value
Exercise Restricted Stock Units 2,000 $0.00 --
Exercise Restricted Stock Units 3,750 $0.00 --
Exercise Restricted Stock Units 2,858 $0.00 --
Exercise Common Stock 2,000 $0.00 --
Exercise Common Stock 3,750 $0.00 --
Exercise Common Stock 2,858 $0.00 --
Sale Common Stock 3,214 $16.6453 $53K
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 28,453 shares (Direct, null)
Footnotes (1)
  1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Shares sold for taxes 3,214 shares Common stock sold April 30, 2026 to cover RSU tax withholding
Weighted average sale price $16.6453 per share Tax-related sale of 3,214 common shares
Sale price range $16.51–$16.78 per share Lowest and highest prices in April 30, 2026 tax-cover trades
Shares acquired via exercises 8,608 shares Exercise/conversion of RSU-related positions on April 30, 2026
restricted stock units ("RSUs") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell to cover financial
"require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
equity incentive plans financial
"mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ring Christine

(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026M2,000A$028,453D
Common Stock04/30/2026M3,750A$032,203D
Common Stock04/30/2026M2,858A$035,061D
Common Stock04/30/2026S(1)3,214D$16.6453(2)31,847D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(3)04/30/2026M2,000 (4) (5)Common Stock2,000$00D
Restricted Stock Units$0(3)04/30/2026M3,750 (6) (5)Common Stock3,750$015,000D
Restricted Stock Units$0(3)04/30/2026M2,858 (7) (5)Common Stock2,858$022,867D
Explanation of Responses:
1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
4. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
5. RSUs do not expire; they either vest or are canceled prior to the vest date.
6. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
7. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring04/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Nurix (NRIX) report for Christine Ring?

Nurix reported that Chief Legal Officer Christine Ring had RSUs vest and converted into common stock, and sold 3,214 shares. The sale was executed solely to cover tax withholding obligations under a mandatory “sell to cover” arrangement, not as a discretionary stock trade.

How many Nurix (NRIX) shares did Christine Ring sell and at what price?

Christine Ring sold 3,214 shares of Nurix common stock at a weighted average price of $16.6453 per share. Footnotes state individual trades ranged from $16.51 to $16.78, and the sales were required to fund tax withholding on RSU vesting.

Were Christine Ring’s Nurix (NRIX) share sales discretionary trades?

No. The filing states the 3,214 shares sold were required to cover tax withholding on restricted stock unit vesting. The issuer’s equity plans mandate a “sell to cover” transaction, meaning the sale was automatic for tax purposes rather than a voluntary market-timing decision.

How many Nurix (NRIX) shares did Christine Ring acquire from RSU vesting?

According to the transaction summary, Christine Ring acquired 8,608 shares of Nurix common stock through exercises or conversions on April 30, 2026. These came from restricted stock units that each represent a contingent right to receive one share of Nurix common stock upon vesting.

How do Nurix (NRIX) restricted stock units work for Christine Ring?

Each restricted stock unit (RSU) represents a contingent right to receive one Nurix common share. The RSUs vest in 12 equal quarterly installments over three years, starting July 30, 2023, 2024, or 2025, provided she continues to serve the company on each vesting date.

Why is there a price range for Christine Ring’s Nurix (NRIX) share sales?

The filing notes a weighted average sale price with trades between $16.51 and $16.78. Multiple trades were executed within that range to satisfy a single tax-withholding obligation, and the company offers to provide detailed trade breakdowns to regulators or stockholders upon request.